Table 1.

FLT3 inhibitors approved in Japan

	Gilteritinib	Quizartinib
FLT3 kinase inhibition IC50 (nM)	0.29	1.6
Inhibitory target	FLT3-ITD, FLT3-TKD	FLT3-ITD
Other targets	AXL, LTK, ALK	KIT
Approved usage and indications in Japan	Single agent for relapsed or refractory AML with FLT3 mutation	Single agent for relapsed or refractory AML with FLT3-ITD mutation